citatuzumab
citatuzumab Basic information
- Product Name:
- citatuzumab
- Synonyms:
-
- citatuzumab
- Conatumumab
- Research Grade Conatumumab(DHA29103)
- TRAIL-R2 mAb|||AMG 655
- Research Grade Citatuzumab
- Research Grade Conatumumab
- CAS:
- 896731-82-1
- MW:
- 0
- Mol File:
- Mol File
citatuzumab Chemical Properties
- form
- Liquid
- color
- Colorless to light yellow
citatuzumab Usage And Synthesis
Uses
Conatumumab (AMG 655) is a human monoclonal agonist antibody against human death receptor 5 (DR5, TRAILR2) (Kd: 1 nM for the long form of DR5, 0.8 nM for the short form of DR5). Conatumumab induces apoptosis via caspase activation. Conatumumab can be used in the research of cancers. [1][2][3].
in vivo
Conatumumab (0-100 μg, i.p., twice weekly) inhibits tumor growth in mice bearing Colo205, H2122, or MiaPaCa2/T2 xenograft tumors[2].
Conatumumab (2.5 μg, i.p., three times per week) enhances the antitumor activity of chemotherapeutics (CPT11, HY-16562) (80 mg/kg) in Colo 205 xenograft[2].
| Animal Model: | Mice bearing Colo205, H2122, or MiaPaCa2/T2 xenograft tumors[2] |
| Dosage: | 0, 0.1, 0.3, 1, 3, 10, 30, 100 μg |
| Administration: | Intraperitoneal injection (i.p.), twice weekly. |
| Result: | Dose-dependently inhibited tumor growth. Induced caspase-3 activation in tumors (determined by IHC). |
References
[1] Herbst RS, et al. A first-in-human study of conatumumab in adult patients with advanced solid tumors. Clin Cancer Res. 2010 Dec 1;16(23):5883-91. DOI:10.1158/1078-0432.CCR-10-0631
[2] Kaplan-Lefko PJ, et al. Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types. Cancer Biol Ther. 2010 Apr 15;9(8):618-31. DOI:10.4161/cbt.9.8.11264
citatuzumabSupplier
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
- Tel
- 15817493340
- 981810490@qq.com
- Tel
- 027-65317797 15926423062
- 422450190@qq.com